Dr Leticia Quintanilla-Martinez is Professor of Pathology and Senior hematopathologist at the University Hospital Tübingen´s Institute for Pathology since 2008.

Dr. Quintanilla-Martinez received her MD from the National University of Mexico. She trained in Internal Medicine and Pathology at the National Institute of Nutrition and Science in Mexico City. She completed her fellowships in hematopathology at the University Hospital in Minneapolis, Minnesota, Southwestern Medical School and Harvard University / Massachusetts General Hospital.

She did her fellowship in molecular pathology at the National Cancer Institute, National Institutes of Health (NIH) in Bethesda. She has received several awards, including the Rokitansky Prize from the Austrian Society of Pathology, The Charlotte-Bühler Stipendium in Austria, the Fogarty Award from the NIH and a Mantle cell lymphoma grant from the Lymphoma Research Foundation.

Dr Quintanilla-Martinez accomplished her “habilitation” (PhD) based on her studies on EBV -associated lymphoproliferative disorders, which are the basis for the WHO classification of EBV-associated lymphoproliferative disorders in children. She and her colleagues have made seminal contributions in several fields of hematopathology, including mantle cell lymphoma, anaplastic large T-cell lymphoma, and, more recently, follicular lymphoma. She has almost 400 publications in peer-reviewed journals and chapters in several books.

She is the co-editor of the recently released 3rd edition of the book, “Hematopathology,” which is the most-read book in the field and a reference in diagnosis. She is a highly cited scientist with a Hirsch index of 65 and a total citations of 14361. She participated in the clinical advisory committee for the revised 4th edition of the WHO classification of lymphomas and, more recently, in the steering committee for the International Consensus Classification (ICC). She is also the leader and author of several chapters in the 5th edition of the WHO series.

Dr Quintanilla-Martinez is active in several professional organisations, including past president of the European Association for Haematopathology (EA4HP, 2020-2022), EXCO member of the Mantle Cell Lymphoma Consortium of the Lymphoma Research Foundation (LRF), the scientific advisory board of the International Conference in Malignant Lymphoma (ICML), member of the International Lymphoma Study Group (ILSG), member of the clinical advisory committee (CAC) for the classification of lymphomas. She is an associate editor of Virchow´s Archive, Modern Pathology and Blood Cancer Discovery and a reviewer in several pathology and haematology journals.

Professor Steven Le Gouill is the Director of the Institut Curie Hospital group (Paris, Saint-Cloud, Orsay; France), Since 2021.

He is an MD specialising in haematology. He graduated from the Medical University of Nantes with a PhD specialising in “blood cells biology” and from Université Paris Cité (former Descartes Paris). Professor Le Gouill has been a postdoc at Dana-Farber Cancer Institute (Harvard Medical School, Boston, USA).

He was appointed a University Professor in 2010 at Nantes Medical University until 2022 and then at Versailles Saint-Quentin Medical University. He served at Nantes Medical University (France) from 1996 to 2021, where he was Head of the Hematology Department (2018-2021), Head of the Oncology and Immunology PHU (2021), and Head of the Early Phase Clinical Investigation Unit (2013-2021). From 2016 to 2021, he was a member of the management board of Nantes University Hospital and Medical Director of the Clinical Research Department and Investigation (DRCI) from 2013 to 2017.

Professor Le Gouill is an international expert in lymphoma with a high focus on Mantle cell lymphoma, a rare lymphoma entity. He published as the first author in major international peer-reviewed journals, including the New England Journal of Medicine, the Journal of Clinical Oncology and the British Journal of Medicine, Blood. 

He is a member of the management board of the LYSA (Lymphoma Study Association), for which he is a member of the Executive Board. He is a member of numerous academic societies, including The French Society of Hematology (SFH), the American Society of Hematology (ASH) and the European Society of Medical Oncology (ESMO). Professor Le Gouill has also been the National Coordinator of the French National CAR-T Registry (DESCAR-T). Professor Le Gouill was awarded numerous prizes in his field of expertise, including the French Society of Hematology Prize in 2017.

Dr Kate Cwynarski is a Haem-Oncologist specialising in Lymphoma at University College London Hospital, London, UK, and an Honorary Associate Professor at UCL.

She received her MRC-funded PhD in immunology at Imperial College, London, UK. Her sub-specialist interests include Central Nervous System (CNS) Lymphoma, T-cell Lymphomas, HIV-related lymphomas, PTLD, and high-grade B-cell lymphomas. She is involved in CAR-T cell trials for refractory DLBCL and T-cell lymphomas.

She leads the UK T cell Lymphoma Group and previously led the UK CNSL Group and the British Society for Haematology (BSH) Lymphoma Specialist Interest Group. She is involved in many clinical trials and has led and

co-authored BSH, EHA, and BHIVA guidelines for the management of SCNSL, PCNSL, CNS prophylaxis, T cell lymphoma, and primary mediastinal B cell lymphoma. She has co-authored more than 100 journal articles.

Dr Martin Hutchings is a haemato-oncologist and a senior consultant from the Department of Haematology, Rigshospitalet, Copenhagen University Hospital and a professor of haematology at the University of Copenhagen. He is responsible for lymphoma treatment and clinical research and founded Denmark’s only dedicated Phase 1 unit for experimental treatment of haematological malignancies, which is a leading site for early development of lymphoma immunotherapy

After obtaining his medical degree and master’s degree (2000), he trained in nuclear medicine until pursuing his current specialisation in clinical oncology.

In 2006, he defended his PhD on PET/CT in Hodgkin lymphoma. Dr Hutchings is an active member of various research groups, including the EORTC Lymphoma Group, which he chaired from 2013 until 2017. He leads several clinical and translational studies in the field of lymphoma, with an emphasis on phase 1 haematology studies and on phase 2 and 3 Hodgkin lymphoma and mantle cell lymphoma while maintaining a special scientific interest in the role of molecular imaging of malignant lymphoma. He is a prolific lecturer, educator, and research supervisor.